

SEQUOIA STUDY

...for Active CNV Secondary to AMD



SEQUOIA STUDY

...for Active CNV Secondary to AMD

To assess the safety and efficacy of abicipar compared with ranibizumab in treatment-naive patients with neovascular age-related macular degeneration (AMD)

*Principal Investigator
Dr. Michael Wells*

INCLUSION / EXCLUSION CRITERIA:

- 50 years of age or older at the time of informed consent
- CNV secondary to AMD
- Best corrected visual acuity in the study eye between 20/40 and 20/300
- Sufficiently clear ocular media and adequate pupil dilation
- Area of the CNV lesion, including both classic and occult components, must be > 50% of the total lesion area
- Any prior or current systemic or ocular treatment for neovascular AMD, approved or investigational, except dietary supplements or vitamins
- No total lesion size > 12 DA (30.5 mm² including blood, neovascularization, and fibrosis), and no macular scar or fibrosis, making up > 50% of total lesion area
- No History or clinical evidence of diabetic retinopathy, diabetic macular edema (DME) or retinal vascular disease other than AMD
- No PPV, Submacular surgery or other surgical interventions for AMD, Incisional glaucoma surgery, Cataract or refractive surgery (excluding YAG laser posterior capsulotomy) within the last 3 months

CONTACT Havener Eye Institute Research Office • 614-293-5287 or • Research@osumc.edu

Kim Rickard • 614-293-9161